ABSTRACT
OBJECTIVE To explore the intervention effect and related mechanism of Tongxinluo capsule on renal fibrosis in rats with diabetic nephropathy （DN）. METHODS Eight rats were selected as control group （ordinary feed）， the remaining rats were given high-glucose and high-fat diet combined with ip injection of streptozotocin （35 mg/kg） to induce DN model. Model rats were randomly divided into model group （purified water）， irbesartan group （positive control， 14.12 mg/kg） and Tongxinluo capsule group （0.3 g/kg）， including 12 rats in the model group and 11 rats for each of the other two groups. All groups were given relevant medicine or water intragastrically， once a day， for 16 consecutive weeks. After the last medication， fasting blood glucose and 24 h urinary total protein （24 h UTP） were detected. Pathological changes in renal cortex of rats in each group were observed. Serum levels of tissue-type plasminogen activator （PA） and plasminogen activator inhibitor 1 （PAI-1） were measured. mRNA expressions of transforming growth factor-β（1 TGF-β1）， type Ⅳ collagen（COL-Ⅳ）， Wnt4 and β-catenin in renal cortex of rats were detected. The protein depositions or expressions of TGF-β1， COL-Ⅳ， focal adhesion kinase （FAK）， integrin-linked kinase （ILK）， E-cadherin， PA， PAI-1， Wnt4 and β-catenin in renal cortex of rats were observed or determined. RESULTS Compared with model group， 24 h UTP of rats in Tongxinluo capsule group were all significantly reduced （P＜0.05）； pathological damage and fibrosis of renal cortex were relieved； the expression of PA in serum and renal cortex was significantly increased， while PAI-1 level was significantly reduced （P＜0.05）； the depositions of COL-Ⅳ and TGF-β1 in renal cortex were all reduced， and corresponding mRNA expression was decreased significantly （P＜0.05）； the depositions of ILK and FAK were decreased， while the deposition of E-cadherin was increased； protein and mRNA expressions of Wnt4 and β-catenin were significantly reduced （P＜0.05）. CONCLUSIONS Tongxinluo capsule can relieve pathological damage to renal tissue and renal fibrosis of DN model rats， and reduce extracellular matrix deposition. The mechanism may be related to regulation of fibrinolytic system activity， the decrease of ILK and FAK expression， and inhibition of Wnt/β-catenin signaling pathway.
ABSTRACT
Objective:To investigate the effects of Tongxinluo capsule on the improvement of cardiac function and the expression of myocardial enzyme spectrum in patients with coronary heart disease after percutaneous coronary intervention (PCI).Methods:One hundred patients with coronary heart disease after PCI who received treatment in Hebei Xianghe County People′s Hospitalfrom April 2018 to April 2020 were enrolled and randomly divided into the observation group and the control group. The control group was given conventional treatment, while the observation group was treated with Tongxinluo capsule on the basis of the control group. Patients in both groups were treated for 3 months. The normal clinical remission after treatment was observed in the two groups. The improvement of cardiac function index left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEF) and myocardial enzyme index aspartate aminotransferase (AST), creatine kinase (CK), creatine kinase isoenzyme - MB (CK - MB), lactate dehydrogenase (LDH), troponin T (TnT) were compared between the two groups before and after the treatment.Results:After treated for 3 months, the total effective rate in the observation group was higher than that in the control group: 92.0%(46/50) vs. 76.0%(38/50), the difference was statistically significant ( χ2 = 4.76, P<0.05). After treated for 3 months, the levels of LVEDV and LVESV in two groups were decreased, and the level of LVEF in two groups was increased, and the levels of LVEDV and LVESV in the observation group were lower than those in the control group: (153.39 ± 8.35) ml/m 2 vs. (155.57 ± 9.32) ml/m 2, (103.49 ± 9.25) ml/m 2 vs. (109.65 ± 10.46) ml/m 2; the levels of LVEF in the observation group was higher than that in the control group: (58.14 ± 7.41)% vs. (54.59 ± 6.92)%, the differences were statistically significant ( P<0.05). After treated for 3 months, the levels of AST, CK, CK-MB, LDH, TnT in two groups were decreased, and the levels of above index in the observation group were lower than those in the control group: (38.14 ± 7.28) U/L vs. (45.04 ± 8.12) U/L, (637.15 ± 75.25) U/L vs. (756.24 ± 85.24) U/L, (553.28 ± 53.14) U/L vs. (632.17 ± 62.81) U/L, (162.43 ± 15.41) U/L vs. (181.74 ± 19.25) U/L, (0.32 ± 0.15) μg/L vs. (0.39 ± 0.11) μg/L, the differences were statistically significant ( P<0.05). Conclusions:The application of Tongxinluo capsule in patients with coronary heart disease after PCI can effectively alleviate clinical symptoms, improve cardiac function, and regulate the enzyme activity of the body.
ABSTRACT
Objective:To study the protective effect of Tongxinluo capsule on cerebral ischemia-reperfusion injury, and explore the mechanism of Tongxinluo capsule in treating cerebral ischemia through network pharmacology. Method:The C57BL/6 mouse middle cerebral artery occlusion(MCAO) model was established by improved suture method and divided into sham operation group, model group, low, medium and high-dose Tongxinluo groups (crude drug 1,2,4 g·kg-1, intragastric administration), Aspirin group (2.055 g·L-1, intraperitoneal injection). Then, neurological function score and 2,3,5-triphenyltetrazole chloride(TTC) staining method were used to determine the infarct size of mice at 24, 48, 72 h by cerebral ischemia-reperfusion. First, chemical constituents of Tongxinluo capsule were screened from the BATMAN-TCM database, and the targets were analyzed. Then, gene ontology (GO) enrichment and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis were performed, and traditional Chinese medicine(TCM)-active ingredient-target network was constructed. Finally, the multi-dimensional pharmacological mechanism of Tongxinluo capsule in the treatment of cerebral ischemia was predicted. Result:Longa score, HE staining and TTC staining all suggested that Tongxinluo capsule could alleviate brain injury in mice after cerebral ischemia and reperfusion, and the improvement degree of Tongxinluo capsule on brain injury was gradually enhanced with the increase of Tongxinluo capsule dose. A total of 132 active components and 240 intersection targets, including cyclic adenosine monophosphate(cAMP)-dependent protein kinase catalytic subunit alpha (PRKACA), adenylate cyclase 1(ADCY1), serine/threonine kinase 1 (Akt1), dopamine receptor D2 (DRD2) and discs large homolog 4 (DLG4) were screened from 12 TCM in Tongxinluo capsule. GO was enriched in cationic channel activity, ion gated channel activity, gate channel activity, neurotransmitter receptor activity, ion channel activity, etc. KEGG was enriched in cAMP signaling pathway, calcium signaling pathway, neuroactive ligand-receptor interaction, cyclic guanosine monophosphate(cGMP)/protein kinase G(PKG) signaling pathway and dopaminergic synaptic signaling pathway. Conclusion:Tongxinluo capsule can alleviate brain damage in mice with cerebral ischemia-reperfusion, and achieve brain protection through multiple targets and multiple links. Network pharmacology reveals effective components，targets and pathway of Tongxinluo capsule in the treatment of cerebral ischemia, which provides theoretical support for the mechanism of Tongxinluo capsule in the treatment of cerebral ischemia.
ABSTRACT
Objective To analyze the clinical effect of Tongxinluo capsule in the treatment of female patients with microvascular angina .Methods 122 female patients with microvascular angina pectoris were selected ,and they were randomly divided into conventional group and observation group ,61 cases in each group .On the basis of the two groups in the same treatment ,including antiplatelet ,lipid,the observation group was given Tongxinluo capsule orally , treatment for 3 months.The therapeutic effect was compared between the two groups .Results The total effective rate of the observation group was 93.44％,which of the conventional group was 80.33％,the difference between the two groups was statistically significant (χ2 =4.603,P=4.603).The total effective rate of exercise electrocardiogram ( ECG ) improvement in the observation group was 91.80％, which of the conventional group was 75.41％, the difference between the two groups was statistically significant (χ2 =4.552,P=0.048).Conclusion Tongxinluo capsule in the treatment of female patients with microvascular angina pectoris has good clinical curative effect ,it can obviously improve the clinical symptoms ,promote disease recover ,which is worthy of popularizing .
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of Tongxinluo Capsule (, TXL) for patients with cardiac syndrome X (CSX).</p><p><b>METHODS</b>Randomized controlled trials (RCTs) regarding TXL in the treatment of CSX were searched in Chinese Biomedicine Literature Database, China National Knowledge Infrastructure, Chinese Scientific Journal Database, Wanfang Database, PubMed, EMBASE, Cochrane Central Register of Controlled Trial, websites of the Chinese and International Clinical Trial Registry platform up to June 30, 2015. The intervention was either TXL alone or TXL combined with conventional treatment, while the control intervention was conventional treatment with or without placebo. Data extraction, methodological quality assessment and data analyses were performed according to the Cochrane criteria. The primary outcome was a composite event of death, acute myocardial infarction (AMI), angina requiring hospitalization, revascularization, and heart failure. The secondary outcome measures were angina symptom improvement, electrocardiograph (ECG) improvement, and serum endothelin-1 (ET-1) level. The adverse events were also recorded. RevMan 5.3 software was applied for data analyses.</p><p><b>RESULTS</b>Twelve RCTs (696 patients) were included. Compared with conventional treatment, the addition of TXL to conventional treatment showed some benefits on relieving angina symptoms [risk ratio (RR): 1.46, 95% confidence interval (CI) (1.25, 1.71), P<0.01], and improving ECG [RR: 1.45, 95% CI (1.21, 1.74), P<0.01]. The pooled result did not support a benefit of TXL on reducing the incidence of primary outcome [RR: 0.20, 95% CI (0.02, 1.61), P=0.13]. In addition, TXL decreased serum ET-1 concentration of CSX patients [standardized mean number:-1.63, 95% CI (-2.29,-0.96), P<0.01]. No serious adverse events were reported.</p><p><b>CONCLUSIONS</b>TXL documents potential benefits on attenuating angina symptoms, improving ECG and decreasing serum ET-1 level for CSX patients. However, more rigorous RCTs with high quality are needed to confirm its efficacy and safety.</p>
Subject(s)
Humans , Middle Aged , Capsules , Cardiovascular Diseases , Diagnostic Imaging , Drug Therapy , Drugs, Chinese Herbal , Therapeutic Uses , Electrocardiography , Endothelin-1 , Blood , Outcome Assessment, Health Care , Publication Bias , SyndromeABSTRACT
Globally, stroke is the second leading cause of death and a major global disability. In China, it has exceeded heart disease to become the leading cause of death. Thus, it is urgent to prevent and treat stroke, particularly ischemic stroke. At present, except the tissue plasminogen activator (tPA) only therapy for ischemic stroke with proven efficacy, the others still lack evidence of evidence-based medicine or their curative effects are insufficient. However, in recent years, Chinese medicine, such as Tongxinluo Capsule, in treatment of ischemic stroke has attracted extensive attention. This article reviewed the research progress in mechanisms of Tongxinluo Capsule in treatment of ischemic stroke from two aspects: vascular protection and neuroprotection.
ABSTRACT
Objective To investigate the effect of Tongxinluo capsule combined with metoprolol on elderly patients with coronary heart disease and angina pectoris and its influence on hemorheology and inflammatory factors.Methods 135 elderly patients with angina pectoris of coronary heart disease were selected,and they were randomly divided into treatment group (68 cases) and control group (67 cases).The treatment group was treated with Tongxinluo capsule combined with metoprolol,while the control group was treated with metoprolol.The two groups were treated for 8 weeks.The curative effect of the two groups was compared,the number and duration of angina pectoris,the changes of hemorheology and inflammatory factors before and after treatment were compared.Results The total effective rate of the treatment group (94.12％) was higher than 76.12％ of the control group (P ＜ 0.05).After treatment,the frequency and duration of angina pectoris in the treatment group were (6.03 ± 1.21) times/week and (3.02 ± 0.76) min/time,respectively,which were significantly lower than those in the control group [(9.87 ± 1.46) times/week and (4.86 ± 0.98) min/time] (t =16.649,12.201,all P ＜ 0.05).After treatment,the whole blood viscosity at high shear rate [(3.76 ± 0.41) mPa/s],whole blood viscosity in low shear [(8.13 ± 0.76) mPa/s],plasma viscosity [(1.23 ± 0.08) mPa/s],erythrocyte aggregation index [(2.06 ± 0.27)],fibrinogen [(2.46 ± 0.41) g/L] in the treatment group were lower than those in the control group[(4.53 ± 0.52) mPa/s,(9.61 ± 0.89) mPa/s,(2.09 ± 0.27) mPa/s,(2.63 ± 0.35),(3.53 ± 0.62) g/L] (t =9.562,10.396,25.170,10.604,11.844,all P ＜ 0.05).After treatment,the interleukin-6 (IL-6) [(8.49 ± 1.76) pg/mL],intercellular adhesion molecule-1 (ICAM-1)[(85.25 ± 8.92) pg/mL],C reactive protein (CRP) [(8.74 ± 1.76) mg/L] in the treatment group were lower than those in the control group[IL-6 (11.32 ± 2.10) pg/mL,ICAM-1 (103.42 ± 10.72) pg/mL,CRP (14.98 ± 2.24)mg/L] (t =8.491,10.712,18.012,all P＜0.05).Conclusion Tongxinluo capsule combined with metoprolol in the treatment of elderly patients with coronary heart disease angina pectoris has obvious curative effect,and can improve the patients'blood rheology and inflammatory reaction.
ABSTRACT
OBJECTIVE:To investigate the effects of Tongxinluo capsules on the levels of serum cyclophilin A (CyPA) and matrix metalloproteinase-9 (MMP-9) in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI).METHODS:A total of 115 CHD patients undergoing PCI were randomly divided into control group (59 cases) and observation group (56 cases).Control group was given conventional treatment.Observation group was additionally given Tongxinluo capsules 0.78 g,3 times a day,for consecutive 6 months,on the basis of control group.The levels of CyPA and MMP-9 as well as the occurrence of ADR were observed in 2 groups before and after treatment.RESULTS:Before treatment,there was no statistical significance in serum level of CyPA and MMP-9 between 2 groups (P＞0.05).The levels of CyPA in 2 groups 1 d and 1 month after surgery as well as the level of CyPA in control group 6 months after surgery were all significantly higher than before surgery,but the observation group was significantly lower than the control group 1 and 6 months,this index was decreased gradually as time,with statistical significance (P＜0.05).There was no statistical significance in the levels of CyPA between 2 groups 1 d after surgery or in observation group between 6 months after surgery and before surgery (P＞0.05).The levels of MMP-9 in 2 groups 1 d and 1 month after surgery were significantly higher than before surgery,and the observation group was significantly lower than the control group,this index was decreased gradually as time,with statistical significance (P＜0.05).There was no statistical significance in the levels of MMP-9 of 2 groups between 6 months after surgery and before surgery(P＞0.05).There was no statistical significance in the incidence of ADR between 2 groups (P＞0.05).CONCLUSIONS:Based on routine treatment,Tongxinluo capsules can significantly reduce the levels of CyPA and MMP-9 in CHD patients after PCI.
ABSTRACT
Objective To study the effects of Tongxinluo capsule and Shen Mai injection in treatment of patients with acute myocardial infarction and its effects on level of left ventricular ejection fraction (LVEF),high sensitive C-reactive protein (hs-CRP),natriuretic peptide (BNP) and QT in acute decompensated heart failure ( QTcd) .Methods 82 patients with acute decompensated heart failure were selected in our hospital from May 2014 to April 2015, those patiens were divided into observation group and control group according to the method of lottery, 41 cases each group.The control group was treated with basic treatment and Huangxin injection, and the obsevation group was treated with Tongxinluo capsule on the basis of the control group.The changes of blood pressure, heart rate, LVEF, hs-CRP, BNP and QTcd were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the observation group was significantly higher than the control group [92.68% (38/41) vs 60.97%(25/41)](P<0.05).The heart rate of the observation group was significantly lower than the control group (P<0.05), but the blood pressure level of the two groups had no significant difference.The levels of BNP, hs-CRP and QTcd in the observation group were significantly higher than the control group [(45.98 ±4.57)% vs(39.07 ±3.12)%](P<0.05) L, BNP, hs-CRP and QTcd were significantly lower than the control group [(2432.12 ± 114.32)ng/L,(17.32 ±1.87) mg/L, (34.76 ±3.02) ms vs (3565.87 ±174.76) ng/L, (14.08 ±1.23) mg/L,(38.45 ±3.86)].Adverse reactions were not observed in the observation group and the control group.Conclusion Tongxinluo capsule combined with Shen Mai injection can effectively increase the left ventricular ejection fraction and reduce hs-CRP, BNP and QTcd in patients with acute decompensated heart failure.The clinical curative effect is good and the safety is high.
ABSTRACT
Objective To observe the effect of Tongxinluo capsule combined with Jinlidas intervention on vascular endothelial fuction and blood glucose in the patients with Type 2 diabetes. Methods A total of 100 patients with Type 2 diabetes were randomly divided into treatment and control groups with 50 patients each. Both groups were received subcutaneous injection insulin, oral admistration of Simvastatin and Aspirin. And the treatment group were received Tongxinluo capsule and Jinlida sintervention based on the standard treatment. The changes of serum levels of FPG, 2hPG, HbAlc, VEGF, NO, ET-1 were observed before and after treatement. All the patients were treated for 12 weeks. Results After the treatment, the serum of FPG (7.03 ± 2.11 mmol/L vs. 8.09 ± 2.03 mmol/L, t=1.911), 2hPG (9.27 ± 2.03 mmol/L vs. 12.06 ± 3.54 mmol/L, t=1.946), HbAlc (6.98%± 1.58%vs. 8.06% ± 2.13%, t=2.013) were decreasd (P<0.05). Besides, VEGF (684.61 ± 84.37 ng/L vs. 514.28 ± 79.52 ng/L, t=2.136), NO (43.28 ± 6.40 ng/L vs. 34.64 ± 6.70 ng/L, t=2.097) of treatment group were siginificantly higher than the control group (P<0.05), while ET-1 (53.13 ± 7.24μmol/L vs. 60.09 ± 7.18μmol/L, t=2.271) were siginificantly lower (P<0.05). Conclusion Tongxinluo capsule combined with Jinlida sintervention could decreased the level Blood glucose and improve vascular endothelial fuction in the patients with Type 2 diabetes.
ABSTRACT
Aim To investigate the effects of Tongxin-luo capsule on oxidative stress in diabetic peripheral neuropathy (DPN )mice and its mechanisms.Meth-ods KK/Upj-Ay mice were divided into model, Tongxinluo low-dose group, Tongxinluo middle-dose group and Tongxinluo high-dose group.C57BL/6 mice were selected as control group.Mice were given drugs intragastrically for 12 weeks.Paw withdrawal latency, motor nerve conduction velocity (MNCV)were detec-ted.Activity of superoxide dismutase (SOD),gluta-thione peroxidase (GSH-Px)and content of malondial-dehyde (MDA)in blood were detected by colorimetric method.The expression of heme oxygenase-1 (HO-1 ),γ-glutamyl cysteine synthetase (γ-GCS ) of sciatic nerve was examined by real time PCR and Western blot.The protein expression of p38 MAPK,p-p38 MAPK,JNK,p-JNK,ERK,p-ERK was examined by Western blot.Results Compared with model group, paw withdrawal latency was increased and MNCV was faster in Tongxinluo group (P <0.05 ,P <0.0 1 ). SOD and GSH-Px contents significantly increased, MDA content decreased (P <0.01 ).HO-1,γ-GCS mRNA and protein expression significantly increased (P<0.05,P <0.01 )in Tongxinluo group.p-p38 MAPK protein expression decreased in Tongxinluo group (P<0.05 ).Conclusion Tongxinluo can in-hibit oxidative stress in DPN of mice via suppressing the phosphorylation of p38 MAPK.
ABSTRACT
Aim To observe the expressions of KLF4 in the myocardium of diabetic mice and their changes under Tongxinluo capsule intervention. Methods For-ty KK/Upj-Ay mice were randomly divided into diabet-ic model group(n=10)and diabetic model with Tongx-inluo(TXL low,middle,high) groups(n =10,respec-tively). C57BL/6 mice were selected as control group ( n=10 ) . At the end of the 3 th month the mice were sacrificed and were weighed. The fasting blood-glucose (FBG),glycosylated hemoglobin(HbA1c),triglyceride ( TG) ,total cholesterol ( TC ) and insulin ( FINS ) were measured to calculate HOMA-IR. Radioimmunoassay was used to measure serum TNF-αand IL-6 . The path-ological changes in the myocardium of mice were ob-served by HE staining. KLF4 mRNA was examined by Real-time PCR, while KLF4 and NF-κB protein were measured by Western blot. Results Compared to the control group,FBG,HbA1c,TG,TC,FINS,HOMA-IR, TNF-α and IL-6 in model group were markedly in-creased;the expressions of myocardial KLF4 were markedly decreased and the expression of nuclear NF-κB protein were markedly increased ( P 0. 05). Conclu-sions KLF4 may be involved in the development of myocardial injury during diabetes. Tongxinluo capsule can ameliorate the myocardial damage and improve the function of diabetic myocardium by up-regulating the expression of KLF4 and inhibiting the activation of NF-κB inflammatory signal pathway.
ABSTRACT
Objective To investigate the clinical curative effect of Danhong injection and Tongxinluo capsule in treating patients with cerebral Infarction. Methods Eighty cerebral infarction patients of Neurology Department in Kailuan General Hospital Affiliated to Hebei United University were selected and randomly divided into control and treatment groups. Patients in the control group were received the based therapy,and patients in treatment group were received Danhong injection and Tongxinluo capsule besides the based therapy. The levels of homocysteine(Hcy),blood lipid,blood viscosity were measured at before treatment,the 14th day,1 month and 3 months after the treatment. All data were analyzed by SPSS13. 0. Results (1)The levels of Hcy,total cholesterol( TC),triglyceride( TG)and blood viscosity( high shear viscosity,low shear viscosity and hematocrit)in treatment group were significantly different from the control group at the 14th day after treatment(P < 0. 05).(2)The levels of TC,TG,HDL-C,LDL-C and blood viscosity in patients of the treatment group at 1 month and 3 months after treatment were different from those of the control group( P< 0. 05). Meanwhile,the levels of TC,TG,HDL-C,LDL-C and blood viscosity in patients of the treatment group at the 14th day after treament were significant different from those of 3 month after treatment(P < 0. 05).(3) The levels of TG,HDL-C,LDL-C and hematocrit in patients of the control group at 3 months after treatment were significantly different from those at pre-treatment(P < 0. 05). The CHOL and TG levels of the control group were different from those at pre-treatment at the 14th day after treatment( P < 0. 05).(4)There were significant differences between two groups at the 14th day,1 month and 3months after treatment in terms of therapy effect(Z= 5. 21,5. 54,3. 86;P = 0. 031,0. 024,0. 048). Conclusion The therapy of Danhong injection combined with Tongxinluo capsule can reduce the levels of Hcy,blood lipid,blood viscosity,and then improve the prognosis of patients with cerebral infarction.
ABSTRACT
OBJECTIVE: To observe the effects of Tongxinluo capsule on platelet activity and function of vascular endothelium at different stages after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome. METHODS: One hundred and sixty patients with acute coronary syndrome were randomly divided into Tongxinluo (TXL) treatment group (TXL group, 80 patients) and conventional treatment group (conventional group, 80 patients). Fifty healthy people were enrolled as control group. The blood levels of CD62p, CD63, glucose protein (GP) II b/III a and endothelium 1 (ET-1), vWF, nitric oxide(NO), and flow-mediated dilatation (FMD) in brachial artery were examined before PCI and the second day after PCI in both groups. Then the patients in TXL group received TXL treatment for 6 months (4 capsule tid), and the above parameters were compared with those of conventional treatment group. RESULTS: The ACS patients' blood levels ofCD62p, CD63, GP II b/III a, vWF and ET-1 increased significantly (P < 0.01), NO and FMD decreased significantly (P < 0.01), compared with control group. The ACS patients' plasma levels of vWF increased significantly (P < 0.05), CD62p, CD63, GP II b/III a and FMD decreased significantly (P < 0.05) after PCI compared with baseline levels. In both TXL group and conventional group, the patients' plasma levels of CD62p, CD63, GP II b/III a, vWF and ET-1 decreased significantly (P < 0.05, P < 0.01) FMD increased significantly (P < 0.05, P < 0.01) compared with baseline levels, meanwhile there were significant differences in all the parameters between TXL group and conventional group (P < 0.01, P < 0.05). In addition, the parameters showed significant differences between 6 months and 2 months after TXL treatment (P < 0.01, P < 0.05). CONCLUSION: TXL can inhibit platelet activity and protect the vascular endothelium function after PCI. Copyright 2012 by the Chinese Pharmaceutical Association.
ABSTRACT
Objective To study the effect of Tongxinluo on the plasma C-reactive protein(CRP)and endothelin-1(ET-1)in acute coronary syndrome(ACS) patients.Methods 100 patients with ACS were randomly divided into conventional therapy group and treatment group(conventional therapy+Tongxinluo gelatin capsule).The changes of CRP and ET-1 in the first day,7th and 14th day were observed.Results In the treatment group,CRP and ET-1 were significantly decreased in the 7th and 14th day(P＜0.05,P＜0.01),and there was significant decrease only in the 14th day(P＜0.05)in the conventional therapy group.CRP and ET-1 levels in the treatment group were significantly different as compared with conventional thereapy group(P＜0.01).Conclusion Tongxinluo capsule may protect blood vessel endothelium through inhibiting CRP and ET-1 to decrease the inflammatory response of endangium.
ABSTRACT
Objective To evaluate clinical efficiency of Tongxinluo capsule in the treatment of stable angina pectoris.Methods Patients(n=98) were randomLy divided into two groups.The treatment group of 50 patients received Tongxinluo capsule 1.14g,po,tid for 4 WK.The control group of 48 patients received Isosrbide dinitrate 10 mg,po,tid for 4 WK.Results The clinical and electrocadiogram(ECG) effective rates of the treatment group were 70.0% and 48.0%respectively,which were significantly higher than 45.8%and 22.9%of the control group,P
ABSTRACT
Objective To observe the clinical efficacy of Tongxinluo Capsule on hypertension with interaction of phlegm and blood stasis, context stagnation or Qi deficiency and blood stasis, and its impact on blood rheology. Methods One hundred and forty-seven cases of hypertension were randomly divided into treatment group (74 cases) and control group (73 cases). Both groups were given conventional antihypertensive and lipid-lowering treatment, and the treatment group was given Tongxinluo Capsule additionally. Symptom score, blood pressure, lipid and rheology of two groups were observed before and after treatment. Results There was no significant difference between before and after treatment in hemorheology and blood lipid of two groups (P
ABSTRACT
Objective: To investigate the mechanisms of curative effect of Tongxinluo capsule(通心络胶囊) on patients with coronary artery disease and angina pectoris.Methods: One hundred and twelve cases in accord with the diagnostic criteria of coronary heart disease of World Health Organization(WHO) were(randomly) divided into two groups: treatment group(n=60) and control group(n=52).The patients in both groups were treated with routine therapy including ?receptor retardant and ester of nitric acid etc.(Additionally),the treatment group was treated with Tongxinluo capsules,2 capsules each time and 2 times(per day) for 2 months consecutively.The clinical manifestations before and after treatment,the changes of(electrocardiogram)(ECG),microcirculation of nail bed and hemorrheology were observed in all the patients in both groups.Results: The total clinical effective rate and the rate of total improvement in ECG changes were 86.67% and 80.00% respectively after treatment in the treatment group,and compared with the control group(78.85% and 69.23%) the differences were significant(both P
ABSTRACT
AIM:To explore the dynamic changes of ET,NO,SOD and MDA in atherosclerosis obliterans(ASO) rabbits,as well as the effects of Tongxinluo Capsule(Radix et Rhizoma Ginseng,Hirudo,Scorpio,Eupolyphaga seu Steleophaga,etc.)(TXL) and the candidate mechanisms. METHODS: Rabbits were randomly divided into 7 groups: sham,model,TXL(0.8,0.4,0.2 g/kg),Tongsaimai tablet(0.8 g/kg) and Laishike((0.002 g/kg)).The animal model of ASO was established with a combined method of mechanical trauma,immunologic injury and high fat fodder feeding.Rabbits were administrated the drugs for 8 weeks after surgery.The levels of ET,NO,SOD and MDA were determined at the time points below: pre-experiment,pre-drug administration,4 weeks after drug administration,8 weeks after drug administration,12 weeks after drug administration.The histopathological changes in iliofemoral artery were examined after opacification. RESULTS: TXL significantly extenuated the decrease in the caliber of the iliofemoral artery of the injured hind limb and decreased MDA content while increased SOD activity and NO content in serum. CONCLUSION: TXL might show effects on improving endothelial cell dysfunction,clearing free radicals and antagonizing lipid peroxidation,which might be the candidate mechanisms for the prevention and treatment of TXL for ASO.
ABSTRACT
OBJECTIVE:To observe the effect of Tongxinluo capsule on the hemorheology of patients with coronary heart disease(CHD). METHODS:120 patients with CHD were randomly divided into 2 groups:60 case in the control group were as-signed to receive combined therapy plus Compound danshen tablets (3 tablets/time,tid),and 60 cases in treatment group to receive additional Tongxinluo capsules(3 capsules/ time,tid) in addition to the therapy applied for the control group. All patients were treated for 4 weeks during this period of time the lipid-lowering drugs and anticoagulants were discontinued. RESULT:The decreasing rates of hemorheology indexes were superior in the treatment group than in control group(P